Law360, New York (May 14, 2012, 1:49 PM ET) -- Takeda Pharmaceutical Co. Ltd. on Friday urged a judge to dismiss a former contractor’s False Claims Act suits accusing the drugmaker of purposely concealing unsafe drug interactions in four treatments for gout, heartburn and diabetes, saying she hasn’t stated a valid claim.
Takeda told a Massachusetts federal judge that Dr. Helen Ge’s assertions that the drugmaker failed to adequately notify the U.S. Food and Drug Administration of potential adverse effects of its gout treatment Uloric, gastroesophogeal reflux disease treatments Dexilant and Prevacid and diabetes treatment Actos...
Takeda Calls FCA Suit Over Unsafe Drug Interactions Baseless
To view the full article, take a free trial now.
